What Is BPC-157? A Complete Research Introduction

Last Updated: July 8, 2026 | Reading Time: Approximately 8 minutes | Author: Palmetto Peptides Research Team

---

Quick Answer

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. Comprising 15 amino acids (sequence: GEPPPGKPADDAGLV), it has been the subject of extensive preclinical research since the early 1990s. Animal model studies have examined its effects across gastrointestinal tissue, musculoskeletal repair, neurological protection, and vascular signaling — making it one of the most broadly studied research peptides in the preclinical literature.

---

Research Notice: This article covers research on BPC-157 research peptide — available from Palmetto Peptides for laboratory use only.

Research Use Only Disclaimer: All peptides listed on this page are sold exclusively for in vitro and legitimate laboratory research purposes. They are not intended for human consumption, veterinary use, or any clinical application. The information in this article is for scientific and educational reference only and does not constitute medical advice. All research use must comply with applicable federal, state, and institutional regulations. Palmetto Peptides complies fully with all applicable FDA guidelines.

What Is BPC-157?

BPC-157 is a synthetic peptide fragment derived from Body Protection Compound, a naturally occurring protein isolated from human gastric juice. The compound consists of 15 amino acids in the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV), giving it a molecular weight of approximately 1419.5 Da.

Unlike many endogenous peptides, BPC-157 demonstrates unusual stability in the presence of gastric acid — the environment from which it was originally isolated. This acid resistance, combined with its relatively small size, has made it a practical and consistent subject for preclinical study across multiple delivery routes and tissue models.

The compound was first characterized by Dr. Predrag Sikiric and colleagues at the University of Zagreb in the early 1990s. Since then, it has accumulated one of the largest bodies of published preclinical literature of any synthetic peptide, with hundreds of peer-reviewed animal studies spanning gastroenterology, orthopedics, neurology, and vascular biology.

Molecular Properties

• Molecular formula: C₆₂H₉₈N₁₆O₂₂
• Molecular weight: 1419.5 Da
• Sequence: GEPPPGKPADDAGLV (15 amino acids)
• Origin: Fragment of human gastric juice BPC protein
• Form (research use): Lyophilized powder; requires reconstitution with bacteriostatic water
• Stability: Resistant to gastric acid hydrolysis; stable under standard laboratory storage conditions
• Research purity standard: ≥98% (HPLC verified)

Discovery and Research History

BPC-157 was initially isolated as part of research into the cytoprotective properties of gastric juice. The stomach produces a range of protective factors that shield its own mucosal lining from the corrosive acid environment — and researchers identified BPC as one of these factors. The 157-amino acid fragment (hence "BPC-157") proved to be the most stable and biologically active portion, making it the focus of subsequent research.

Early studies from the Zagreb group focused primarily on GI applications, examining healing effects in models of stomach ulcers, inflammatory bowel disease, and esophageal damage. As the compound's mechanisms were characterized — particularly its interactions with growth hormone receptors, nitric oxide (NO) synthesis, and vascular endothelial growth factor (VEGF) — research expanded substantially into other tissue systems.

By the 2010s, BPC-157 had become one of the most-published synthetic peptides in the preclinical literature, with studies examining its effects in virtually every major organ system in rodent models.

Primary Research Areas

Published preclinical research has investigated BPC-157 across four major domains:

Gastrointestinal Research: The original and most extensively studied application. Animal models have examined BPC-157's effects on gastric mucosal healing, inflammatory bowel markers, fistula closure, short bowel syndrome, and esophageal injury. Researchers have noted its resistance to gastric acid as particularly relevant for GI tissue-system studies.

Musculoskeletal Research: A large body of rodent studies has examined tendon, ligament, bone, and muscle injury models. BPC-157 is frequently studied alongside TB-500 in this space — the two peptides appear to act through complementary rather than overlapping mechanisms, making them natural subjects for combination research.

Neurological Research: More recent publications have examined BPC-157 in CNS injury models, including peripheral nerve damage, traumatic brain injury, and dopaminergic system protection. Studies have examined potential interactions with serotonin, dopamine, and GABA signaling pathways in rodent models.

Vascular Research: BPC-157 has been studied in the context of angiogenesis and wound closure. Its interaction with nitric oxide pathways and VEGF signaling has been a consistent focus, with researchers examining effects on blood vessel formation in wound healing models.

Mechanisms Under Investigation

Several molecular mechanisms have been identified and studied in the preclinical BPC-157 literature:

• Growth hormone receptor interaction: BPC-157 appears to interact with GH receptor signaling pathways, which may contribute to its tissue repair effects in animal models.
• Nitric oxide (NO) modulation: Studies have examined BPC-157's effects on both nitric oxide synthase (NOS) expression and NO availability in tissue repair contexts.
• VEGF pathway interaction: BPC-157 has been shown to influence VEGF expression in wound healing and angiogenesis models, potentially explaining some of its observed effects on vascular tissue.
• Tendon fibroblast activity: In vitro studies have examined BPC-157's effects on tenocyte proliferation and collagen synthesis.

BPC-157 vs Other Research Peptides

BPC-157 occupies a unique niche in research peptide biology: it is one of the few synthetic peptides with a substantial body of published in vivo animal data across multiple organ systems. Most peptides are studied within a narrow application domain. BPC-157's breadth of study — and the consistency of observations across independent research groups — has made it a reference compound in tissue repair research.

Its most frequent research partner is TB-500 (the active region of Thymosin Beta-4). Where BPC-157 acts primarily through GH receptor and NO signaling for localized effects, TB-500 operates through actin polymerization and cell migration for more systemic tissue remodeling. The combination — often called the Wolverine Stack — covers complementary repair pathways and has been widely studied in musculoskeletal models.

Research Grade Quality Standards

For laboratory use, BPC-157 should meet the following specifications:

• Purity ≥98% verified by HPLC analysis
• Batch-specific Certificate of Analysis (COA) from ISO-accredited laboratory
• Lyophilized powder form (not pre-dissolved)
• Proper cold-chain handling during shipping
• Clear labeling with lot number, purity, and expiration

Third-party testing by an independent, ISO-accredited laboratory is the gold standard. Reputable suppliers provide batch-specific COAs — not generic or copy-pasted certificates.

Sourcing BPC-157 for Research

Research-grade BPC-157 is available as lyophilized powder from qualified peptide suppliers. When evaluating suppliers, researchers should verify: purity claims backed by third-party HPLC data, proper cold-chain shipping, clear research-use-only labeling, and responsive technical support for laboratory questions.

Palmetto Peptides BPC-157 is available in 5mg and 10mg variants, with ≥98% purity verified by COA-backed batch testing. Also available as the BPC-157 + TB-500 Wolverine Stack for researchers studying combined tissue repair mechanisms.